Therapeutic proteins and antibodies represent a $125 billion annual market. Chinese Hamster Ovary (CHO) derived cell lines are the preferred host cells for the production of therapeutic proteins. Here, we present a draft genomic sequence of the CHO-K1 ancestral cell line. The assembly comprises 2.45Gb genomic sequence with 24,383 predicted genes. We associate most scaffolds to 21 microfluidically-isolated chromosomes to identify chromosomal locations of genes. Furthermore, we investigate genes involved in glycosylation, which affects therapeutic protein quality, and viral susceptibility genes, which affect cell engineering and regulatory concerns. Specifically, homologs for most human glycosylation-associated genes are identified in the CHO-K1 genome, although 141 are not expressed under exponential growth. In addition, many important viral entry genes are present in the genome but not expressed, which may explain the unusual viral resistance property of CHO cell lines. We demonstrate how the availability of this genome sequence may facilitate genome-scale science for biopharmaceutical protein production.

Transitional cell carcinoma (TCC) is the most common type of bladder cancer. Here we sequenced the exomes of nine individuals with TCC and screened all the somatically mutated genes in a prevalence set of 88 additional individuals with TCC with different tumor stages and grades. In our study, we discovered a variety of genes previously unknown to be mutated in TCC. Notably, we identified genetic aberrations of the chromatin remodeling genes (UTX, MLL-MLL3, CREBBP-EP300, NCOR1, ARID1A and CHD6) in 59% of our 97 subjects with TCC. Of these genes, we showed UTX to be altered substantially more frequently in tumors of low stages and grades, highlighting its potential role in the classification and diagnosis of bladder cancer. Our results provide an overview of the genetic basis of TCC and suggest that aberration of chromatin regulation might be a hallmark of bladder cancer.

Clear cell renal cell carcinoma (ccRCC) is the most common kidney cancer and has very few mutations that are shared between different patients. To better understand the intratumoral genetics underlying mutations of ccRCC, we carried out single-cell exome sequencing on a ccRCC tumor and its adjacent kidney tissue. Our data indicate that this tumor was unlikely to have resulted from mutations in VHL and PBRM1. Quantitative population genetic analysis indicates that the tumor did not contain any significant clonal subpopulations and also showed that mutations that had different allele frequencies within the population also had different mutation spectrums. Analyses of these data allowed us to delineate a detailed intratumoral genetic landscape at a single-cell level. Our pilot study demonstrates that ccRCC may be more genetically complex than previously thought and provides information that can lead to new ways to investigate individual tumors, with the aim of developing more effective cellular targeted therapies.